Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer’s disease.
from Dementia Big http://ift.tt/2dweUKo via alcoholic dementia
http://ift.tt/2diIO5O
No comments:
Post a Comment